Kristina Buder

Kristina Buder

Auto-generated profile, based on publicly available information

Kristina Buder

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2013 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
KBKristina Buder
Kristina Buder
AGAnja Gesierich
Anja Gesierich
GGGötz Gelbrich
Götz Gelbrich
MGMatthias Goebeler
Matthias Goebeler
Up to 50% of patients with uveal melanoma develop metastatic disease with poor prognosis. Regional, mainly liver‐directed, therapies may induce limited tumor responses but do not improve overall survival. Response rates of metastatic uveal melanoma (MUM) to systemic chemotherapy are poor. Insights into the molecular biology of MUM recently led to investigation of new drugs. In this study, to compare response rates of systemic treatment for MUM we searched Pubmed/Web of Knowledge databases and ASCO website (1980–2013) for “metastatic/uveal/melanoma” and “melanoma/eye.” Forty studies (one case series, three phase I, five pilot, 22 nonrandomized, and two randomized phase II, one randomized phase III study, data of three expanded access programs, three retrospective studies) with 841 evaluable patients were included in the numeric outcome analysis. Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies. Progression‐free survival ranged from 1.8 to 7.2, median overall survival from 5.2 to 19.0 months as reported in 21/40 and 26/40 studies, respectively. Best responses were seen for chemoimmunotherapy (ORR 10.3%; 95% CI 4.8–18.7%) though mainly in first‐line patients. Immunotherapy with ipilimumab, antiangiogenetic approaches, and kinase inhibitors have not yet proven to be superior to chemotherapy. MEK inhibitors are currently investigated in a phase II trial with promising preliminary data. Despite new insights into genetic and molecular background of MUM, satisfying systemic treatment approaches are currently lacking. Study results of innovative treatment strategies are urgently awaited.

17 April 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KBKristina Buder
Kristina Buder
CLConstantin Lapa
Constantin Lapa
Michael Christoph KreisslMichael Christoph Kreissl
Michael Christoph Kreissl
ASAndreas Schirbel
Andreas Schirbel
KHKen Herrmann
Ken Herrmann
JBJürgen C Becker
Jürgen C Becker
Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.

19 December 2013 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
KBKristina Buder
Kristina Buder
SRSabrina Ruppert
Sabrina Ruppert
ATAxel Trautmann
Axel Trautmann
EBEva‐Bettina Bröcker
Eva‐Bettina Bröcker
MGMatthias Goebeler
Matthias Goebeler
AKAndreas Kerstan
Andreas Kerstan